Prophylactic therapy against PCP pneumonia and herpes viral infections is recommended upon initiation of therapy and for at least 2 months following last dose.
- TRADE NAMES: Campath (Bayer); MabCampath (Schering)
- INDICATIONS: B-cell chronic lymphcyotic leukemia, non-Hodgkin's lymphoma
- CLASS: Biologic, Immunosuppressant, Monoclonal antibody
- HALF-LIFE: 12 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Ponesimod
- See adverse reactions attributed to class:
CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of alembuzumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/02/2023
